NIH to review first human use of CRISPR gene editing

NIH's Office of Science Policy said the agency's Recombinant DNA Advisory Committee (RAC) will meet June 21-22 to discuss a proposed Phase I trial using CRISPR/ Cas9 gene editing as part of a chimeric antigen receptor (CAR) T cell therapy. NIH said the study would be the first human use of CRISPR/Cas9 technology.

NIH spokesperson Renate Myles told BioCentury that University of Pennsylvania professor Edward Stadtmauer is to present the trial protocol, titled "Phase I Trial of Autologous T Cells Engineered to Express NYESO-1 TCR and Gene Edited to Eliminate Endogenous TCR and PD-1." ...